We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.

About Inocal

InoCal was created to be inotropic drug and vasopressor calculator application .

InoCal was created to be inotropic drug and vasopressor calculator application. This innovative application can assist and facilitate healthcare providers to prevent medication errors such as prescription error, transcribing error, dispensing error, and administration error. InoCal can also provide seamless and efficient communications between medical personnel for transferring critically ill patients between wards, intensive care units, and hospitals. The purpose of InoCal is to increase patient safety in accordance with the principle and policy of the World Health Organization (WHO) that “Medication safety for patient safety”.

Key features

- Available on both Android and iOS devices

- A stand-alone application, not related to hospital database

- Unlimited patient’s profile creations

- Unlimited inotropic drugs and vasopressors selections

- Beautiful and perspicuous infographic data presentation

If you have any feature requests or suggestions, please contact

E-mail: [email protected]

Facebook: https://www.facebook.com/ผ่าตัดหัวใจ-โรงพยาบาล-มอ-CVT-Surgery-PSU-102839785424213

What's New in the Latest Version 1.0

Last updated on May 6, 2022

Minor bug fixes and improvements. Install or update to the newest version to check it out!

Translation Loading...

Additional APP Information

Latest Version

Request Inocal Update 1.0

Requires Android

4.1

Show More

Inocal Screenshots

Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.